53915-75-6

Basic information

• Product Name: Benzene, 1,1'-[(2-bromoethoxy)methylene]bis[4-fluoro-
• Synonyms: 1-bromo-2-[bis(4-fluorophenyl)methoxy]ethane;bis(p-fluorophenyl)methoxyethyl bromide;2-di(p-fluorophenyl)-methoxyethyl bromide;Benzene,1,1'-[(2-bromoethoxy)methylene]bis[4-fluoro;1-[bis(4-fluorophenyl)methoxy]-2-bromoethane;4,4'-difluorobenzhydryl 2-bromoethyl ether
• CAS NO: 53915-75-6
• Molecular Formula: C15H13BrF2O
• Molecular Weight: 327.168
• Mol File: 53915-75-6.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Benzene, 1,1'-[(2-bromoethoxy)methylene]bis[4-fluoro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzene, 1,1'-[(2-bromoethoxy)methylene]bis[4-fluoro-(53915-75-6)
• EPA Substance Registry System: Benzene, 1,1'-[(2-bromoethoxy)methylene]bis[4-fluoro-(53915-75-6)

Safety Data

• Hazardous Substances Data: 53915-75-6(Hazardous Substances Data)

Upstream product

• 345-90-4 bis(4-fluorophenyl)methylbromide 
• 540-51-2 2-bromoethanol 
• 365-24-2 4,4'-difluorobenzhydryl alcohol 

Downstream Products

• 145532-89-4 N-<2-ethyl>-1-methyl-2-phenylethylamine 
• 96122-90-6 1-<2-(4,4'-difluorobenzhydryloxy)ethyl>-4-(3-<2-(4,4'-difluorobenzhydryloxy)ethyl>-2-oxo-benzimidazol-1-yl)-1,2,3,6-tetrahydropyridine 
• 143747-40-4 1-<2-ethyl>-3-piperidinecarboxylic acid 
• 50366-32-0 2-[bis(p-fluorophenyl)-methoxy]ethylamine 
• 246235-98-3 N-(3-{2-[bis-(4-fluoro-phenyl)-methoxy]-ethylamino}-propyl)-2-phenyl-acetamide 

Relevant articles and documents

Novel (bisarylmethoxy)butylpiperidine analogues as neurotransmitter transporter inhibitors with activity at dopamine receptor sites

A series of (bisarylmethoxy)butylpiperidine derivatives was prepared and evaluated in vitro and in vivo to determine the structural requirements necessary for dual activity at the DAT and DA/5-HT receptor sites. These hybrid ligands, constructed by combining pharmacophores specific for the DAT and DA/5-HT receptors, could be useful drugs for treating cocaine addiction by assisting cocaine addicts in maintaining abstinence. The series was evaluated in vitro for DAT and DA/5-HT receptor activity and then selected compounds were tested in vivo for their effects on cocaine-induced hyperlocomotor activity (LMA). The majority of the new compounds demonstrated high to moderate affinity (4-191 nM) for the DAT with 4-hydroxy-4-phenylpiperidine analogues 14 and 15 possessing the greatest affinity. Compounds 15 and 22 exhibited the highest ratio of reuptake inhibition-to-binding (discrimination ratio, DR), 111 and 323, respectively. These derivatives had modest affinity and antagonistic activity for dopamine D2/D3 receptors. Compounds 9 and 15 (DR=0.9 and 111, respectively) stimulated locomotor activity, whereas the other compounds suppressed this response. All compounds tested except for 17 and 21 attenuated cocaine-induced hyperlocomotion.

Structure-Activity Studies on Benzhydrol-Containing Nipecotic Acid and Guvacine Derivatives as Potent, Orally-Active Inhibitors of GABA Uptake

The introduction of lipophilic groups onto the ring nitrogen of nipecotic acid and guvacine, two known GABA uptake inhibitors, afforded potent, orally-active anticonvulsant drugs.A series of compounds is reported which explores the structure-activity relationships (SAR) in this series.Among the areas explored: side-chain SAR (aromatic-, heterocyclic-, and tricyclic-containing side chains) and modifications to the tetrahydropyridine ring.The benzhydrol ether-containing side chains afforded the most potent compounds with several exhibiting in vitro IC50 values for GABA uptake of 1 μM (including 5, Table I; 37, 43, Table IV; and 44, Table V).Compound 44 was selected for extensive evaluation and subsequently progressed to Phase 1 clinical trials with severe adverse effects seen after single dose administration to humans.

Potential antiparkinsonic agents: Synthesis and pharmacology of some 4-fluoro-4'-halogenobenzhydryl-2-(N,N-disubstituted amino)ethyl ethers

-